To investigate treatment-induced changes in tumour CXCL12/CXCR4 signalling and the immune cell microenvironment, mice bearing the OCICx 20 model were treated with RT or RTCT for 3 weeks (30 Gy) and concurrent or adjuvant plerixafor for 3 weeks. This evidence concerns the gene CXCL12 and neoplasm.